Appy times: Venaxis back on track
This article was originally published in Clinica
After a long road with its APPY1 appendicitis test, Venaxis (formerly AspenBio Pharma) could finally be turning the corner. US FDA approval of the diagnostic is expected in the first half of 2014, according to Canaccord Genuity analyst Jeff Frelick, who rates the company’s stock as “buy” with a target price of $7. Its shares on the Nasdaq Capital Market closed at $2.16 on 27 March.